Working with the World Health Organization (WHO) and its Essential Medicines Lists disease-related and evidence-based cases are made for additions of drugs to treat children with cancer. This impacts national essential medicines lists (NEMLs) in low and middle income countries that guide procurement of medicines. Ongoing studies with WHO assess the uptake of additions to NEMLs as a measure of access to cancer chemotherapeutic agents and drugs used for the supportive care of children with cancer. Barriers to access are explored so that these can be targeted for removal.
Impact
Improving access to drugs is an imperative step to enhancing the care of children with cancer in low and middle income countries that will result in higher rates of cure. Advocating with WHO and national governments to standardise their NEMLs and bring then up to date is an important step in the process. Such advocacy is pursued with organisations such as the Union for International Cancer Control (UICC), Childhood Cancer International and Non-Communicable Disease-Child acting in concert
Student Experience
None at this time
Countries
Switzerland
Impact
Research, Global Partnerships
Institutional Partner(s)
UICC, Childhood Cancer International and NCD Child
Community Partner(s)
Industry Partner(s)
Key Outcomes
Publications
Sponsorship
Foreign
Sponsorship Details
UICC is the leading advocate for improving access to cancer chemotherapy
